Roche buys Singapore facility from Lonza

Global healthcare firm Roche, through its subsidiary Genentech, will acquire a Singapore manufacturing facility from Lonza for up to $360 million.

Global healthcare firm Roche will buy a Singapore biologic manufacturing facility for up to $360 million from chemical and biotechnology firm Lonza , the two firms said yesterday.

Basel-based Roche will buy the facility through its San Francisco-headquartered subsidiary Genentech, which it acquired earlier this year. The acquisition price of $360 million has two components a $290 million upfront payment and a $70 million milestone-based payment.

After the takeover, the Lonza facility will be merged with Genentech Singapore's existing facility....

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: roche | lonza | genentech | avastin | singapore | finance | asia

Print Edition

FinanceAsia Print Edition